Trends in Atrial Fibrillation‐Related Mortality Among Adults With Obesity in the United States From 1999 to 2024
Obesity Science & Practice · 2026-06 · 12 (3)
DOI: 10.1002/osp4.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity Science & Practice, online erschienen am 10.06.2026. Verfasst von Aymen Ahmed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endeavor Center for Cardiovascular Intervention Outcomes Research and Evaluation (ECCORE) Section of Interventional Cardiology Endeavor Health Cardio…. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with increased mortality, particularly among individuals with obesity. This study examined trends in AF‐related mortality in adults with obesity in the United States from 1999 to 2024.
Methods
Trends in AF‐related mortality in adults with obesity aged ≥ 25 years with obesity were analyzed using the Centers for Disease Control and Prevention Wide‐ranging Online Data for Epidemiologic Research (CDC WONDER) database. AF and obesity were considered as multiple causes of death. Age‐adjusted mortality rates (AAMRs) per 1,000,000 were analyzed using Joinpoint regression to identify trends and calculate average annual percentage change (AAPC) stratified by gender, race, and region.
Results
A total of 63,853 deaths were identified. From 1999 to 2024, AF‐related mortality rates increased from 1.9 in 1999 to 20.8 in 2024 (AAPC: 11.4 [95% CI: 10.4, 12.2]). Males recorded higher AAMRs than females. White individuals exhibited higher AAMRs than Blacks. Nonmetropolitan areas (9.6) had higher AAMR than metropolitan areas (7.4). The Midwest recorded the highest AAMR while the South reported the steepest rise. States in the top 90th percentile of AAMR were Vermont, Oklahoma, Oregon, Minnesota, and Wyoming.
Conclusion
AF‐ and obesity‐related mortality has increased overall from 1999 to 2024, with higher mortality rates observed in men, White individuals, nonmetropolitan areas, and the Southern US region. These findings highlight the need for continued surveillance and targeted prevention efforts in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endeavor Center for Cardiovascular Intervention Outcomes Research and Evaluation (ECCORE) Section of Interventional Cardiology Endeavor Health Cardiovascular Institute Glenview Illinois USA.
- The University of Chicago Pritzker School of Medicine Chicago Illinois USA.
- Department of Medicine Dow University of Health Sciences Karachi Pakistan.
- Baylor Scott and White Research Institute Dallas Texas USA.
- Department of Medicine HCA Houston Healthcare Clear Lake/University of Houston Webster Texas USA.
- Division of Preventive Cardiology Houston Methodist Academic Institute Houston Texas USA.
ORCID-Profile: Saad Ahmed Waqas, Hasibullah Aminpoor, Muhammad Talha Ayub
Zitieren
APA
Ahmed, A., Batool, R. M., Waqas, S. A., Siddiqui, H. F., Arshad, M. S., Paryani, N. S., Shahid, I., Aminpoor, H., Mithani, A., & Ayub, M. T. (2026). Trends in Atrial Fibrillation‐Related Mortality Among Adults With Obesity in the United States From 1999 to 2024. Obesity Science & Practice, 12(3). https://doi.org/10.1002/osp4.70160
Vancouver
Ahmed A, Batool RM, Waqas SA, Siddiqui HF, Arshad MS, Paryani NS, et al. Trends in Atrial Fibrillation‐Related Mortality Among Adults With Obesity in the United States From 1999 to 2024. Obesity Science & Practice. 2026;12(3). doi:10.1002/osp4.70160
BibTeX
@article{Ahmed2026,
author = {Ahmed, Aymen and Batool, Ruqiat Masooma and Waqas, Saad Ahmed and Siddiqui, Hasan Fareed and Arshad, Muhammad Sameer and Paryani, Neha Saleem and Shahid, Izza and Aminpoor, Hasibullah and Mithani, Ali and Ayub, Muhammad Talha},
title = {Trends in Atrial Fibrillation‐Related Mortality Among Adults With Obesity in the United States From 1999 to 2024},
journal = {Obesity Science & Practice},
year = {2026},
volume = {12},
number = {3},
doi = {10.1002/osp4.70160}
}
EUVIMED